Pharvaris Netherlands B.v.
Clinical trials sponsored by Pharvaris Netherlands B.v., explained in plain language.
-
New daily pill could stop HAE attacks in their tracks
Disease control OngoingThis study tests a once-daily pill called deucrictibant to prevent painful swelling attacks in people aged 12 and older with hereditary angioedema (HAE). Participants receive either the drug or a placebo for 24 weeks to see if it reduces attack frequency. The goal is to provide a…
Phase: PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New pill could quickly stop swelling attacks in hereditary angioedema
Disease control ENROLLING_BY_INVITATIONThis study is testing an oral medication called deucrictibant for quickly treating swelling attacks in people with hereditary angioedema (HAE), including dangerous throat swelling. It involves 150 adults who have previously been in related studies or are new to the drug. The goal…
Phase: PHASE2, PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated May 11, 2026 20:53 UTC